Minneapolis, Minnesota -- Biotechnology company Celcuity has received $2.15 million in equity venture capital funding, according to an SEC regulatory filing.
Celcuity has developed a proprietary functional cellular analysis platform that "directly assesses the functionality of the disease-related signaling pathways of a patient's diseased cells ex vivo."
The system also determines whether a particular drug therapy is having the effect on those cells over time.
Investors in the financing were not disclosed, nor was how the company intends to use the proceeds.
A total of 12 investors participated in the offering.
Celcuity is still seeking $3 million in additional equity investment, according to the filing.